Role of rasagiline in treating Parkinson’s disease: Effect on disease progression

Rasagiline is a second generation, selective, irreversible monoamine oxidase type B (MAO-B) inhibitor. It has demonstrated efficacy in monotherapy for early Parkinson’s disease (PD) patients in one large randomized, placebo-controlled trial (TVP-1012 in Early Monotherapy for Parkinson’s Disease Outp...

Full description

Saved in:
Bibliographic Details
Main Authors: Malaty, Irene A, Fernandez, Hubert H
Format: Artigo
Language:Inglês
Published: Dove Medical Press 2009
Subjects:
Review
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC2695242/
https://ncbi.nlm.nih.gov/pubmed/19753135
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items